276 related articles for article (PubMed ID: 31637717)
1. miR-181a/b-5p ameliorates inflammatory response in monocrotaline-induced pulmonary arterial hypertension by targeting endocan.
Zhao H; Guo Y; Sun Y; Zhang N; Wang X
J Cell Physiol; 2020 May; 235(5):4422-4433. PubMed ID: 31637717
[TBL] [Abstract][Full Text] [Related]
2. miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Zhao H; Wang Y; Zhang X; Guo Y; Wang X
Toxicol Appl Pharmacol; 2020 Jan; 386():114827. PubMed ID: 31734320
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension.
Zhao H; Xue Y; Guo Y; Sun Y; Liu D; Wang X
Int Immunopharmacol; 2017 Jan; 42():115-121. PubMed ID: 27912147
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-140-5p targeting tumor necrosis factor-α prevents pulmonary arterial hypertension.
Zhu TT; Zhang WF; Yin YL; Liu YH; Song P; Xu J; Zhang MX; Li P
J Cell Physiol; 2019 Jun; 234(6):9535-9550. PubMed ID: 30367500
[TBL] [Abstract][Full Text] [Related]
5. MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways.
Cai Z; Li J; Zhuang Q; Zhang X; Yuan A; Shen L; Kang K; Qu B; Tang Y; Pu J; Gou D; Shen J
Exp Mol Med; 2018 Apr; 50(4):1-11. PubMed ID: 29700287
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-663 prevents monocrotaline-induced pulmonary arterial hypertension by targeting TGF-β1/smad2/3 signaling.
Li P; Song J; Du H; Lu Y; Dong S; Zhou S; Guo Z; Wu H; Zhao X; Qin Y; Zhu N
J Mol Cell Cardiol; 2021 Dec; 161():9-22. PubMed ID: 34339758
[TBL] [Abstract][Full Text] [Related]
7. miR-1226-3p Promotes eNOS Expression of Pulmonary Arterial Endothelial Cells to Mitigate Hypertension in Rats via Targeting Profilin-1.
Jian J; Xia L
Biomed Res Int; 2021; 2021():1724722. PubMed ID: 34778448
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a.
Li F; Wang D; Wang H; Chen L; Sun X; Wan Y
Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322
[TBL] [Abstract][Full Text] [Related]
9. In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression.
Le Ribeuz H; Courboulin A; Ghigna MR; Lambert M; Hautefort A; Humbert M; Montani D; Cohen-Kaminsky S; Perros F; Antigny F
Respir Res; 2020 Jul; 21(1):186. PubMed ID: 32678044
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro.
Liu HM; Jia Y; Zhang YX; Yan J; Liao N; Li XH; Tang Y
Acta Pharmacol Sin; 2019 Apr; 40(4):477-485. PubMed ID: 30038339
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats.
Tang C; Luo Y; Li S; Huang B; Xu S; Li L
Biomed Pharmacother; 2021 Jan; 133():111081. PubMed ID: 33378977
[TBL] [Abstract][Full Text] [Related]
12. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
13. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
14. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
[TBL] [Abstract][Full Text] [Related]
15. Cold exposure aggravates pulmonary arterial hypertension through increased miR-146a-5p, miR-155-5p and cytokines TNF-α, IL-1β, and IL-6.
Sánchez-Gloria JL; Carbó R; Buelna-Chontal M; Osorio-Alonso H; Henández-Díazcouder A; de la Fuente-León RL; Sandoval J; Sánchez F; Rubio-Gayosso I; Sánchez-Muñoz F
Life Sci; 2021 Dec; 287():120091. PubMed ID: 34717910
[TBL] [Abstract][Full Text] [Related]
16. Grape seed proanthocyanidin inhibits monocrotaline-induced pulmonary arterial hypertension via attenuating inflammation: in vivo and in vitro studies.
Chen F; Wang H; Zhao J; Yan J; Meng H; Zhan H; Chen L; Yuan L
J Nutr Biochem; 2019 May; 67():72-77. PubMed ID: 30856466
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
18. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.
Yu M; Wu X; Wang J; He M; Han H; Hu S; Xu J; Yang M; Tan Q; Wang Y; Wang H; Xie W; Kong H
Int J Med Sci; 2022; 19(4):681-694. PubMed ID: 35582418
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-335-5p Contributes to Right Ventricular Remodeling via Calumenin in Pulmonary Arterial Hypertension.
Ma H; Ye P; Zhang AK; Yu WD; Lin S; Zheng YG
Biomed Res Int; 2022; 2022():9294148. PubMed ID: 36246958
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of cold-inducible RNA-binding protein exacerbated monocrotaline-induced pulmonary artery hypertension through Caveolin1 and CAVIN1.
Liu J; Ke X; Wang L; Zhang Y; Yang J
J Cell Mol Med; 2021 May; 25(10):4732-4743. PubMed ID: 33755319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
